Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ChemoMetec ASOCSE:CHEMM +2.57%98 EV-to-OCF is 39.09 as of Aug. 22, 2026, which is 29% below its 10-year median of 55.15. GuruFocus rates OCSE:CHEMM with a GF Score™ of 98/100 and a GF Value™ of kr531.61 (Fairly Valued). The stock has 2 warning signs investors should review. Among 851 Medical Devices & Instruments companies, ChemoMetec AS ranks worse than 87.31% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, ChemoMetec AS's Enterprise Value is kr8,212.5 Mil.
ChemoMetec AS's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was kr210.1 Mil. Therefore, ChemoMetec AS's EV-to-OCF for today is 39.09.
The historical rank and industry rank for ChemoMetec AS's EV-to-OCF or its related term are showing as below:
OCSE:CHEMM'
s EV-to-OCF Range Over the Past 10 Years
Min: 22.71 Med: 55.15 Max: 192.74
Current: 37.09
During the past 13 years, the highest EV-to-OCF of ChemoMetec AS was 192.74. The lowest was 22.71. And the median was 55.15.
OCSE:CHEMM's EV-to-OCF is ranked worse than 87.31% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: 7.54
vs OCSE:CHEMM: 37.09
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ChemoMetec AS's PE Ratio (TTM) for today is calculated as:
ChemoMetec AS's share price for today is kr487.40.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ChemoMetec AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was kr10.170.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
ChemoMetec AS EV-to-OCF Related Terms
ChemoMetec AS EV-to-OCF Historical Data
* Premium members only.
The historical data trend for ChemoMetec AS's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, ChemoMetec AS's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ChemoMetec AS EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ChemoMetec AS's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where ChemoMetec AS's EV-to-OCF falls into.
ChemoMetec AS's current Enterprise Value is kr8,212.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ChemoMetec AS's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was kr210.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ChemoMetec AS (OCSE:CHEMM) has a EV-to-OCF of 39.09 as of Aug. 22, 2026. This is 29% below median its historical median of 55.15. Over the past decade, ChemoMetec AS's EV-to-OCF has ranged from 22.71 to 192.74. According to the industry distribution chart, ChemoMetec AS ranks #743 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 87.3%.
Is ChemoMetec AS's EV-to-OCF too high?
ChemoMetec AS's current EV-to-OCF of 39.09 is 29% below median its 10-year median of 55.15. Over the past 10 years, this metric has ranged from a low of 22.71 to a high of 192.74. The Medical Devices & Instruments industry median EV-to-OCF is 7.54. ChemoMetec AS's value of 39.09 is 418.4% above this industry median. Based on the distribution chart, ChemoMetec AS ranks #743 out of 851 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, ChemoMetec AS has a GF Score™ of 98/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ChemoMetec AS's EV-to-OCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ChemoMetec AS ranks #743 out of 851 companies for EV-to-OCF. This places ChemoMetec AS in the lower half of its industry. The industry median EV-to-OCF is 7.54. ChemoMetec AS's value of 39.09 is 418.4% above this benchmark. Historically, ChemoMetec AS's own EV-to-OCF has ranged from 22.71 to 192.74 over the past decade. While the company's 10-year median is 55.15 vs. the industry median of 7.54, ChemoMetec AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.54, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ChemoMetec AS's current EV-to-OCF of 39.09 is 418.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ChemoMetec AS's current EV-to-OCF is 39.09, which is 29% below median its own 10-year median of 55.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ChemoMetec AS stock overvalued right now?
Based on GuruFocus' analysis, ChemoMetec AS (OCSE:CHEMM) is currently considered Fairly Valued. The stock's GF Value™ is kr531.61, compared to a current price of kr487.40 — trading 8.3% below its estimated fair value. The current EV-to-OCF is 39.09, which is 29% below median its 10-year median of 55.15 and 418.4% above the Medical Devices & Instruments industry median of 7.54. ChemoMetec AS's overall GF Score™ is 98/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For ChemoMetec AS (OCSE:CHEMM), the current EV-to-OCF is 39.09 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ChemoMetec AS (OCSE:CHEMM) Overvalued in 2026?
Based on GuruFocus' analysis, ChemoMetec AS stock appears to be undervalued.
The current stock price of kr487.40 is trading 8.3% below its estimated GF Value™ of kr531.61.
GuruFocus considers ChemoMetec AS to be Fairly Valued.
Key valuation signals for OCSE:CHEMM:
EV-to-OCF: 39.09 (29% below median its 10-year median of 55.15)
GF Value™: kr531.61 vs. price of kr487.40 (8.3% below fair value)
Industry Position: 418.4% above the Medical Devices & Instruments median (#743 of 851)
No single metric tells the full story. See the OCSE:CHEMM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.
98GF Score
Get the complete analysis for OCSE:CHEMM
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:CHEMM has been successfully added to your 
